Yisheng Biopharma completes Phase I clinical trial of PIKA hepatitis B vaccine
Chinese biopharmaceutical company Yisheng Biopharma has completed its Phase I clinical trial of PIKA hepatitis B vaccine to provide prophylactic and therapeutic benefits against hepatitis B virus infection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis B | Hepatitis Vaccine | Pharmaceuticals | Vaccines